v
Search
Advanced

Publications > Journals > Journal of Exploratory Research in Pharmacology > Article Full Text

  • Review Article
  • OPEN ACCESS

Structures, Functions and Therapeutic Potential of Cyclotides

  • Sarfuddin Azmi1,* ,
  • Mohammad Mustafa1,
  • Shoaib Shoaib2 and
  • Mohd Kamil Hussain3,* 
 Author information  Cite
Journal of Exploratory Research in Pharmacology   2022;7(4):234-242

doi: 10.14218/JERP.2022.00029

Abstract

Plants usually produce a large number of secondary metabolites, including antimicrobial peptides rich in cysteine. Phytopeptides, categorized into five to eight groups, exhibit varied lengths, secondary structures, and disulphide bridge patterns. Cyclotides, a specific group, possess an end-to-end cyclic structure with a knot-like disulphide bridge, which are known for their anti-nematode, anti-mollusk, and anti-trematode activities. This review provides comprehensive insights into cyclotides, covering their origin, structural and functional characteristics, therapeutic potential, biotechnological applications, and future prospects. Studies indicate that modifications in cyclotide loop regions do not alter their conformation significantly, a crucial aspect for biotechnological applications. Cyclotides, identified as peptides with a cysteine-knot motif, offer a versatile scaffold for drug delivery and combinatorial libraries due to their high tolerance for sequence variability. Molecular characterization reveals the selective targeting of G-coupled oxytocin and vasopressin receptors by the first identified cyclotide, facilitating endometrial movement during labor onset.

Keywords

Antimicrobial Phytopeptides, Cyclotide, Knottin, Mobious, Baracelet, Trypsin Inhibitor

Introduction

Proteins/peptides play varied and complex roles in all other macromolecules. These provide intracellular and extracellular support for biochemical reaction catalysis, generate receptors and channels in membranes, intracellularly and intercellularly transport chemicals, have hormone function, and defend against biotic and abiotic stress, among other functions in organisms.1 Among the different defense systems, the peptides/proteins produced by almost all organisms provide inherent protection against a wide range of invading organisms.2 These specific protein-protein/protein-peptide interactions can act as medication candidates with therapeutic potentials.3 However, due to instability, low membrane permeability, and inaccessibility to intracellular targets, the therapeutic potential of peptides remains restricted.4

Peptides (naturally produced or synthesized) are typically very susceptible to breakdown in the physiological milieu.5 In order to increase stability, conformation restrictions are introduced on the backbone, and/or side chains of amino acids are modified to provide resistance against enzymatic cleavage. The cyclization and modification of amino acid side chains have been discovered as important tools for the stabilization of peptides in physiological environments. Cyclotides are a family of head-to-tail cyclic phytopeptides with three disulphide bridges of knot topology.6 Intrinsically, cyclotides have different activities, such as antimicrobial, insecticidal, anti-nematodal, anti-mollusk, anti-trematode, anti-HIV, and protease inhibitory, as well as hormone-like activity.7–10 The excellent stability and sequential engineering amenability between the knots of cyclotides provide a great scaffold for drug design. As a result, cyclotides can be viewed as a natural scaffold for combinatorial libraries that are structurally constrained by the cysteine knot and head-to-tail cyclization, allowing these to accept all types of mutations, except for conserved cysteine residues involved in knot.11–13 Furthermore, some cyclotides can interact with intracellular targets by crossing the plasma membrane.14

Discovery

Several decades before, the first cyclotide was recognized from the plant Oldenlandia affinis of the Rubiaceae family, which is being used as traditional tea in an African country. The analysis predicted that the component of uterotonic tea to facilitate birth was a peptide,15,16 although there is no available modern protein chemistry or other technique to elucidate this in detail. Its structural characterization with cyclic nature and the presence of the cysteine knots were elucidated after 1995, and this was named, kalata B.6 Subsequently, many more cyclic peptides similar to Kalata B were isolated from other plants of Rubiaceae and plants in other families, such as Violaceae, Solanaceae, Fabaceae, Cucurbitaceae, and Apocynaceae. Most of the cyclotides have been reported from Rubiaceae and Violaceae.17,18 Furthermore, almost all of the plants in the Violaceae family contain cyclotides, while merely approximately 5% of plants in the Rubiaceae family contain these.18 Cyclotides have been discovered to be distributed across all types of tissues, including the roots, stems, leaves, flowers, and seeds, in some plants.10,19 Furthermore, a plant encompasses 10–160 different cyclotides. An in silico transcriptomic and proteomic study reported that the plant Viola tricolor of Violaceae contained 168 cyclotides, and it was extrapolated that Violaceae can contain approximately 150,000 different cyclotides.20,21 In order to facilitate access to various types of identified cyclotides, a database called, CyBase, was recently developed, and this is publicly available on the website, CyBase.org.au. More than 300 cyclotides have been reported, and these are available on the aforementioned website for the further understanding of proteomics and other characteristics.22

Structural characteristics

A cyclotide, similar to other defense peptides, is derived from a precursor peptide that contains a signal domain/ER domain, an N-terminal prodomain, cyclotide, and a C-terminal prodomain. Sometimes, the flanking sequences of the N and C terminals exhibit a type of repeat known as, the N-terminal repeat (NTR) and C-terminal repeat (CTR), which presumably play important roles in the process of N to C cyclization.23 The indispensable hypothesis of Asparginyl endopeptidase (AEP) suggested that NTR, CTR, and more especially, N-terminal Gly/Ala and C-terminal Asn/Asp may principally be involved in the AEP-mediated N to C amidation. Furthermore, the AEP hypothesis has been validated in the cyclotide-producing plant Momordica cochinchinensis by changing the Asn/Asp amino acid sequence or knocking out the AEP gene.24–27 The recent discovery of linearized cyclotides or acyclotides, with the missing Asn/Asp of the C-terminus or improper CTR, further strengthens the AEP hypothesis of the cyclization of cyclotides.24,28 In the chemical synthesis of cyclotides, disulphide bridges are formed during N to C peptization, while in the biological synthesis, the oxidation of cysteine begins in the precursor peptide, bringing the N and C termini nearby, and facilitating the end-to-end cyclization.27,29 However, the detailed process for the biosynthesis of cyclotides has not been endeavored.

Nuclear magnetic resonance (NMR) spectroscopy is generally used to characterize the three-dimensional structure of small proteins/peptides, although this cannot be used for the characterization of all kinds of proteins/peptides, because a number of peptides remain unordered in the solution state. NMR is an excellent technique for cyclotides, because the highly constrained and knotted structure reinforces the ability of the cyclotide to remain ordered, even in the solution state. Furthermore, NMR can also be employed as a non-invasive technique to evaluate the position of the cysteine, which forms a disulphide knot. However, its validation would require invasive catalytic methods, such as reduction and alkylation.

Cyclotides are plant-origin defense peptides in the cyclic protein/peptide family, which have a higher number, when compared to all other cyclic groups. Furthermore, these are a unique class of defense molecules that comprise of various potential properties. Cyclotides usually have 27–40 amino acids, and head-to-tail cyclic peptides, and these are further stabilized with three disulphide bridges. In cysteine knot topology, disulphide bridges form as a ladder between CysI-CysIV, CysII-CysV and CysIII-CysVI (Fig. 1b). Since cyclization and the cysteine knot provide resilience against chemicals, thermal, and even enzymatic degradation, cyclotides are the only naturally occurring peptides that have been reported to be orally active among peptide therapeutic leads/candidates.22,30–34 Except for the cysteine position, cyclotides are highly tolerant to sequence variations, in terms of topology. Furthermore, cyclotides are structurally and highly constrained, are able to cross the cellular membrane, and have specific affinity for ligands or proteins. The very unusual stability, highly constrained topology, and versatile scaffold of cyclotides fuel great interest to develop potential therapeutic and diagnostic reagents.29,35,36

Tertiary structure and the corresponding schematic representation loop formation in different classes of cyclotides.
Fig. 1  Tertiary structure and the corresponding schematic representation loop formation in different classes of cyclotides.

(a). Tertiary structure: the different size loops provide the differential activity of class Bracelet, Mobius and Trypsin inhibitor, and the connecting line defines the disulphides, which generate the loops. (b). Schematic representation of the loop: C denotes Cys, and the lines that connect these define the pattern of the disulphide bridge, which created loops of variable sizes. The tertiary structure of the different classes of cyclotides and the schematic representation were illustrated using CyBase (CyBase.org.au).

The distinctive property of proline, cis or trans, provides a special feature in the stereometric conformation of proteins/peptides. Cyclotides are largely categorized into the subfamilies of Mobius and Bracelet, based on the cis or trans proline. Cyclotides that contain the cis-proline produce a twisted backbone of 180°, and these are known as Möbiöus, while those that contain the trans-proline are known as Bracelet (Fig. 1).37,38 In known cyclotides, approximately two-thirds belong to Bracelet, and nearly one-third belong to Mobius. Apart from these two subfamilies, there is another minor class of cyclotides known as, trypsin inhibitor.28,37,38 Trypsin inhibitor cyclotides cross cell membranes by utilizing different endocytic pathways, and interacting with various kinds of proteins and ligands. Furthermore, trypsin inhibitors are mainly isolated from the seeds of Momordica cochinchinensis, with a potent inhibition property of Ki = 20–30 pM. Apart from the knot structure, the amino acid contents of trypsin inhibitor cyclotides quite vary. In addition, these cyclotides (trypsin inhibitors) have relatively higher sequencing homology, when compared to the linear cysteine knot squash trypsin inhibitor, which has been often referred to earlier as, acyclic knottins.28 Although all three subfamilies have similar knot topology, except for loop composition, cyclotides in the Bracelet subfamily are larger and more diverse, when compared to those in the Mobius subfamily. Furthermore, compared to both Mobius and Trypsin inhibitors, Bracelet cyclotides offer a more complex situation in in vitro conditions for correct folding. As a result, Bracelet is less thoroughly investigated and employed in various biotechnological applications and characterization, when compared to Mobius and trypsin inhibitors.28

Functional assessment

Cyclotides in the Mobius and Bracelet subfamilies are known as defense peptides in plant systems. The defense peptides of this group mainly have anti-nematode, anti-trematode, and anti-mollusk activity. Similar to other defense peptides, cyclotides exhibit its activity through physical interaction with the membrane, disturbing the normal integrity. As previously documented, when the larvae of Lepidopteran species ingest plant tissues that contain cyclotides, the membrane integrity of midgut line cells becomes damaged, halting the proliferation. Different kalata cyclotides have varying inhibitory activities against the growth of nematode larvae (Haemonchus contortus and Trichostrongylus colubriformis), and ranks from the most potent kalata B6 to the least kalata B3. In addition, cyclotide cyclovoilacin, such as O2, O3, O8 and O13, inhibit larval growth, similar to kalata B1 and B2, but lesser than B6.39 Furthermore, regardless of whether these are from the Mobious and Bracelet groups, cyclotides with 3–4 basic residues usually have higher inhibitory activity in larvae. Mechanistically, cyclotide Kalata B can specifically bind to phosphatidylethanolamine, and promote aggregation, leading to pore formation-mediated cell death.

Cyclotides have antimicrobial and antitumor activity. Similar to most antimicrobial peptides, cyclotides are basically amphipathic, and possess patches of hydrophobic and hydrophilic amino acids. Kalata B1 has potent activity against both Gram-positive and -negative bacteria,7,28 and cycloviolacin O2 has potent activity against Staphylococcus aureus in mice.40 In the in vitro analysis of anti-bacterial testing, the antimicrobial activity of cyclotides was impaired when the bacterial growth media contained high levels of salt.

The detailed molecular characterization revealed that uterotonic cyclotide selectively targets G-coupled oxytocin and vasopressin receptors to promote endometrium movement at the start of labour.21 Cyclotides usually have anticancer activity with adverse hemolytic and cytotoxicity, but the modification of the primary structure or linearization would reduce the adverse toxicity. For example, in two variants of cyclovalcacins (O2 and O13), O2 has a serine and O13 has an alanine at the same position, and O13 has approximately 3–4 fold more hemolytic activity than O2.41 Furthermore, several cyclotides have selective activity against cancerous cells.23,42,43 For example, vingo 5 acts against cervical HeLa cells,44 and a cyclotide isolated from the Chinese plant Hedyotis diffusa (Rubaceae) has potent anti-proliferative and anti-metastasis activity against various prostate cell lines and tumor growth.45 Similarly, the HB7 obtained from Hippocrepis biflora and MCoTI-PMI, which was engineered from MCoTI-I, exhibited tumor suppressor activity in a xenograft model of prostate cancer.46

Therapeutic potential of cyclotides

Cyclotides have gained increasing attention due to its diverse biological properties and potential applications in agronomic and pharmaceutical industries. Furthermore, cyclotides have a common mode of action, and its activity is evaluated by its capacity to bind to target biological membranes, generate pores, and disrupt these. Cyclotides from Fabaceae, Poaceae, Rubiaceae and Violaceae exhibit antibacterial, anti-cancer, hemolytic, nematocidal, antifungal, anti-HIV, insecticidal and molluscicidal activities.47

Anticancer potential of cyclotides

There is a huge library of cyclotides available for screening the anticancer potential against various types of cancer cell lines. Interestingly, cyclotides are a rapidly emerging class of plant-derived cyclic peptides, which exhibit great toxicity against cancerous cell lines. The present study discussed the anti-cancer properties of several cyclotides against a variety of tumors, and the limited information on its mode of action. In addition, the data was tabulated to provide concise information on anticancer cyclotides (Table 1).23,48–59

Table 1

Anti-cancer cyclotides and details, such as source, family/subfamily and IC50

Cytotoxic activity of cyclotides
S.N.CyclotidesPlantFamily/SubfamilyIC50 (µM)Reference
1Chassatide C2Chassalia chartaceaRubiaceae/Bracelet2.4452
2Chassatide C71.2052
3Chassatide C1.0052
4Chassatide C10Rubiaceae/Hybrid5.0052
5Chassatide C11Rubiaceae/Bracelet1.2052
6Cliotide T1Clitoria ternateaFabaceae/Bracelet0.6048
7Cliotide T100.7053
8Cliotide T120.7853
9Cliotide T2Fabaceae/Möbius8.0048,53
10Cliotide T32.0048,53
11Cliotide T7Fabaceae/Bracelet0.7353
12Cter B3.5054
13Cter E2.5054
14Cter G3.0054
15Cycloviolacin O19Viola odorataViolaceae/Bracelet0.5254,55
16Cycloviolacin O30.4254
17Cycloviolacin O4Pombalia calceolariaViola odorataHedyotis diffusa9.8050
18Cycloviolacin O80.80–1.1556
19Hedyotide B5Rubiaceae/Bracelet1.03–1.3249
20Hedyotide B61.85–2.3349
21Hedyotide B70.33–0.6849
22Hedyotide B81.88–3.1149
23Hedyotide B91.14–2.0149
24Mela 1Melicytus latifoliusViolaceae/Möbius2.09–9.8357
25Mela 21.30–19.2657
26Mela 32.04–18.7357
27Mela 42.04–18.7357
28Mela 51.58–11.4257
29Mela 61.58–11.4251
30Tricyclon AViola tricolorViolaceae/Bracelet8.7054
31Poca APombalia calceolaria1.8050
32Poca B2.7050
33Psyle APsychotria leptothyrsaRubiaceae/Bracelet7.77051
34Psyle E0.64–1.7351
35Mram 8Viola philippica1.75–15.557
36Vaby AViola abyssinicaViolaceae/Möbius7.6058
37Vaby D2.6058
38Vibi EViola bifloraViolaceae/Bracelet3.2023
39Vibi G0.9623
40Vibi H1.6023
41Viphi AViola philippica1.75–15.523
42Viphi D1.55–5.2459
43Viphi E1.55–5.2459
44Viphi F1.03–6.3559
45Viphi G1.03–6.3559

A previous study revealed that nucleotide T1 and T4 can suppress HeLa cell proliferation, with an IC50 value of 0.6 µM.48 Hedyotide B5 (HB5), HB6, HB7, HB8 and HB9 were isolated from the leaves and root of Hedyotis biflora, and were found to have cytotoxicity against four pancreatic cancer cell lines. In particular, HB7 inhibited the migration and invasion of capan2 cells and suppressed the tumor growth by reducing the tumor size and weight in a xenograft model.49 A recent study reported that several cyclotides from Viola tricolor, such as verve peptide A, CyO2, CyO13 and kalata B1, suppress the proliferation of glioblastoma U-87MG and SH-SY5Y cells, with IC50 values ranging within 2.15–7.92 µM. Further investigations have revealed that the combination of verve peptide A or CyO2 with temozolomide (TMZ) can enhance the apoptosis of U-87MG cells, suggesting that these cyclotides may increase the efficacy of TMZ chemotherapy against glioblastoma.60 Hyen D is the most abundant cyclotide of the medicinal plant Hybanthus enneaspermus, and has been shown to exert cytotoxic effects on Hela cells, with an IC50 value of 0.92 µM.61 Two cyclotides, Poca A and B, were isolated from the root of Pombalia calceolaria, and it was observed that these can reduce MDA-MB-231 cell viability, while CyO4 can inhibit the proliferation and migration of breast cancer cells.50 Oligopeptides obtained from Momordica charantia, such as MCLO-12, inhibit the proliferation and induce apoptosis in non-small cell lung A549 cancer cells in a dose-dependent manner by suppressing the MAPK-p38 and JNK pathways.62 Recently, a bioactive peptide, IM-7, was reported to suppress the proliferation of leukemia MOLT-4 and NB4 cells in a dose-dependent manner, and induce autophagy and apoptosis by modulating the beclin1, caspase-3 and Bcl-2 expression, and it was also found that IM-7 can enhance the chemotherapeutic effects of daunorubicin.63 Diffusa cyclotide (DC) 1, DC2 and DC3 were purified from the root and leaves of Hedyotis diffusa, and were found to have potent cytotoxicity against prostate cancer PC3, DU145 and LNCaP cells in vitro. In particular, DC3 suppressed the proliferation, migration and invasion of LNCaP cells, and inhibited tumor growth in a xenograft model.64 Previously, the CyO2 of Viola odorata was reported to have the ability to selectively kill highly proliferative tumor cells, and cause cell death by membrane permeabilization. Further investigations have indicated that the combination of CyO2 and doxorubicin can inhibit the proliferation of MCF-7 and drug-resistant MCF-7/ADR cells, highlighting the chemosensitization potential of CyO2 against doxorubicin-resistant breast cancer cells.51 Furthermore, several novel chassatides were isolated from Chassatide chartacea, and chassatide C7, C8 and C11 inhibited the proliferation of HeLa cells, with IC50 values of 1.2, 1.0 and 1.2 µM, respectively.52 Cyclotides obtained from Clitoria ternatea were evaluated for its anticancer and chemosensitizing potential against the A549 and A549/paclitaxel cell lines, and the results indicated that some of these cyclotides can significantly reduce the IC50 of paclitaxel by many folds against lung cancer cells.53 The linoorbitides (LOB) 1, LOB2 and LOB3 obtained from flaxseed have potent anticancer activities against breast cancer MCF-7 and Sk-Br-3, and melanoma A375 cells, in which LOB3 has the most cytotoxic and selective activity.65

Anti-HIV potential of cyclotides

HIV is a potentially fatal virus that targets CD4+ T lymphocytes and macrophages. HIV infection can dramatically reduce CD4+ cells, leading to the onset of AIDS with a set of symptoms. More than 100 cyclotides have been identified for its activities against HIV infection.66 Concise details on anti-HIV cyclotides have been collated, in order to allow readers to view these all at once (Table 2).9,66–71

Table 2

Anti-HIV activity exhibiting cyclotides and details, including source, family/subfamily and EC50

Anti-HIV activity of cyclotides
S.N.CyclotidesPlantFamily/SubfamilyEC50 (µM)Reference
1Circulin AChassalia parvifoliaRubiaceae/Bracelet0.04–0.2667
2Circulin B
3Circulin C0.05–0.2759
4Circulin D
5Circulin E
6Circulin F
7Cycloviolin ALeonia cymosaViolacea/Bracelet0.1368
8Cycloviolin B
9Cycloviolin C
10Cycloviolin D
11Cycloviolacin O13Viola odorata0.3266
12Cycloviolacin O14Violacea/Möbius0.44
13Cycloviolacin O240.30
14Cycloviolacin Y1Viola yedoensisViolaceae/Bracelet1.2169
15Cycloviolacin Y40.20
16Cycloviolacin Y50.04
17Kalata B1Violacea/Möbius0.66
18Vhl-1Viola hederaceaViolaceae/Bracelet0.8770
19PalicoureinPalicourea condensateRubiaceae/Bracelet0.1071

The EC50 value is usually used to evaluate the effectiveness of cyclotides in anti-HIV activity. Various cyclotides have varying anti-HIV activities, with EC50 values ranging within 0.04–1.21 µM. Crude extracts of Chassalia parviflora, circulin A and circulin B have exhibited strong activity against HIV, with an EC50 ranging within 0.04–0.26 µM.67 Subsequently, the in vitro anti-viral activity against HIV of another four cyclotides obtained from Chassalia parviflora, circulin C–F exhibited a similar activity, with an EC50 ranging within 0.05–0.27 µM.9 The cycloviolins A–D obtained from Leonia cymosa exhibit anti-HIV activity, with an EC50 of 0.13 µM.68 Cycloviolacins O13, O14 and O24, and kalata B1 have also exhibited significant anti-HIV activity, with an EC50 value of 0.32, 0.44, 0.30 and 0.66 µM respectively.66,69 The anti-HIV activity of cycloviolacins Y1/Y4/Y5 and kalata B1 exhibit an EC50 of 1.21, 0.20, 0.04 and 0.66 µM, respectively.69 The leaf-specific cyclotide Vhl-1 obtained from Viola hederacea exhibit anti-HIV activity, with an EC50 of 0.87 µM.70 Furthermore, cyclotide palicourein was isolated from Palicourea condensata, and exhibited significant activity against viral strain HIV-1RF in CEM-SS cells, with an EC50 of 0.10 µM.71

Bio-technological applications

Cyclotides can be applied in the industry, such as the utilization of naturally active cyclotides as a bio-insecticide, given that several plants produce insecticidal cyclotides. For instance, cyclotides from the areal part of butterfly pea have potent membrane leakage activity for the insect gut mimicking membrane.32 Subsequently, the butterfly pea areal part contains potential insecticidal cyclotides.34 Recently, the extract obtained from butterfly pea has been demonstrated to contain a bioinsecticide in Australia, and this bioinsecticide (Sero-X) can be commercially used on macadamia nut and cotton crops. Similarly, due to the inhibitory activity of Kalata-B1 against activated peripheral lymphocytes, the direct plausibility of this promising pharmaceutical has led to its application as an immunosuppressant. The subsequent study of the lysine scanning of kalata B1 and the analysis of the antiproliferative activity of prominent active mutant T20K revealed the inhibition of T cell proliferation by downregulating the expression of interleukin-2, its receptor, interferon-γ and tumor necrosis factor (TNF-α).72,73 After several successive in vivo experiments with T20K kalata B1, Cyxone was recently produced, and this is presently being tested in a phase 1 clinical trial as an immunosuppressant.74 Furthermore, cyclotides obtained from Palicourea sessilis were identified as pase A–E, and some of these cyclotides, such as pase A–D, inhibit the proliferation of human lymphocytes in a dose-dependent manner, suggesting that pase cyclotides may work as immunosuppressants.75

As a consequence of high tolerance of sequence variability, cyclotides and other knottin peptides have been developed for the diagnosis, regulation of expression or inhibition, and specific delivery of candidate drugs through the introduction of multiple specific epitopes.29,76 Grafting bioactive epitopes onto specific cyclotide frames can help to stabilize the bioactive epitope and enhance the ability to cross membranes.14 The first pharmacologically active construct of cyclotides was designed by incorporating the vascular endothelial growth factor receptor on multiple loops of kalata B1.77 The goal of the growth factor receptor grafting was to competitively inhibit the interaction between the growth factor and its receptor, in order to stop the proliferation of cancerous cells in the vascular system. In a similar approach, several antagonists were designed by utilizing cell-permeating trypsin inhibitor cyclotides to target cytokine-associated cancers. For instance, angiotensin-1-7 (Ang 1–7) is a peptide hormone that counters against angiotensin II via the MAS receptor, and exhibits vasodilator, anti-proliferative and anti-angiogenic activity. However, its poor stability in serum affects its clinical application. Interestingly, Ang 1–7 grafted in MCoTI-I has good stability, and a comparable affinity for the MAS receptor.33 In addition, several constructs of cyclotides were designed to circumvent cardiovascular problems, neurodegenerative diseases, autoimmune disorders, such as multiple sclerosis, and other inflammatory response, which were probably executed through the modulation of protein-protein interaction.33,78,79

Stabilized scaffolds due to the presence of disulphide knots and cyclic nature offer a window to incorporate biologically active peptides between the backbone of the intra-cysteine sequence, in order to avoid enzymatic degradation. Recently, the oral natural disulphide knot construct, Linzess (guanylate cyclase C agonist), has been approved by the FDA to combat chronic constipation and petulant bowel syndrome,80 bringing great interest for the development of other knottin-based oral drug candidates. The incorporation of bioactive peptides between the cysteines loop of cyclotides or knottin peptides can lead to several successful constructs, such as the orally active analgesic Bradikynin B1 construct developed by grafting the active peptide into kalata B1.81 Similarly, the anti-obesity antagonist candidate molecule was developed through the incorporation of a group of peptide hormones, Melanocortin, with kalata B1.82 Angiogenic peptides, such as laminin and osteopontin, were incorporated into the trypsin inhibitor, MCoTI-II, to develop an antagonist of the vascular endothelial growth factor receptor.83 All these constructs have significant potency and great stability in physiologic conditions. Therefore, the unique characteristic of the very high sequence tolerance of cyclotides can provide a great lead scaffold to construct stable candidate drugs or diagnostic molecules, opening a window for the development of various lead molecules.

Future perspectives

In Australia, the butterfly pea extract known as, Sero-X, has recently been approved as a bioinsecticide for use on macadamia nut and cotton crops. The first cyclotide pharmacologically active construct was created by incorporating the vascular endothelial growth factor receptor on the multiple loops of kalata B1. The recent FDA approval of the oral natural disulphide knot construct, Linzess, against constipation and petulant bowel syndrome has triggered great interest on the development of oral knottin-based drug constructs. In this line, several constructs have been reported, such as analgesic Bradikynin B1, an anti-obesity antagonist by peptide hormone Melanocortin with kalata B1, angiogenic peptides, such as laminin and osteopontin incorporated into trypsin inhibitor MCoTI-II, and others. Due to the numerous biological properties and high tolerance for sequence variability, cyclotides are attracting a lot of attention for its potential applications in the pharmaceutical and agricultural sectors.

Conclusions

In contrast to the animal system, the majority of plant antimicrobial peptides comprise of multiple disulphide bridges, which provide compactness and stability in adverse environments, and even against metabolic enzymes. Cyclotides have high stability against high-temperature and enzymatic degradation. Due to its structure nature, cyclotides can act as stabilized scaffolds to open a window for inserting biologically active peptides between inter-cysteine sequences (loop), in order to avoid enzymatic degradation.

To date, the majority of plant diversity remains unexplored, and cyclotides have only been reported from a few of plant families. Therefore, the present status demands more intensive researches, in order to identify more biologically functional, stable and safe cyclotides, which may benefit humans. Identifying cyclotides can provide the clues and footsteps to the synthetic biology of peptides. At present, the majority of studies have used plant leaves and roots for identifying novel cyclotides. However, it remains unclear whether plant seeds contain novel cyclotides, because cyclotides linoorbitides was reported in the seeds of Linum usitatissimum.

Abbreviations

AEP: 

asparginyl endopeptidase

CTR: 

C-terminal repeat

NMR: 

nuclear magnetic resonance

NTR: 

N-terminal repeat

HB5: 

Hedyotide B5

Declarations

Acknowledgement

The authors thank their respective institutions for the technical and administrative support.

Funding

None.

Conflict of interest

Dr. Sarfuddin Azmi has been an editorial board member of Journal of Exploratory Research in Pharmacology since February 2022. The authors have no other conflicts of interest to declare.

Authors’ contributions

Study concept and design: SA and MKH; acquisition of data: MM and SS; drafting of the manuscript: SA, MM, SS and MKH; critical revision of the manuscript for important intellectual content: SA and MKH; administrative, technical and material support: MM and SA; study supervision: SA, MM, MKH and SS. All authors have made a significant contribution to the study, and approved the final manuscript.

References

  1. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Genomes Project Consortium, et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012;491(7422):56-65 View Article PubMed/NCBI
  2. Azmi S, Hussain MK. Analysis of structures, functions, and transgenicity of phytopeptides defensin and thionin: a review. Beni-Suef Univ J Basic Appl Sci 2021;10:5 View Article
  3. Liu H, Saxena A, Sidhu SS, Wu D. Fc engineering for developing therapeutic bispecific antibodies and novel scaffolds. Front Immunol 2017;8:38 View Article PubMed/NCBI
  4. McGregor DP. Discovering and improving novel peptide therapeutics. Curr Opin Pharmacol 2008;8(5):616-619 View Article PubMed/NCBI
  5. Mollica A, Costante R, Stefanucci A, Novellino E. Cyclotides: a natural combinatorial peptide library or a bioactive sequence player?. J Enzyme Inhib Med Chem 2015;30(4):575-580 View Article PubMed/NCBI
  6. Saether O, Craik DJ, Campbell ID, Sletten K, Juul J, Norman DG. Elucidation of the primary and three-dimensional structure of the uterotonic polypeptide kalata B1. Biochemistry 1995;34(13):4147-4158 View Article PubMed/NCBI
  7. Tam JP, Lu YA, Yang JL, Chiu KW. An unusual structural motif of antimicrobial peptides containing end-to-end macrocycle and cystine-knot disulfides. Proc Natl Acad Sci U S A 1999;96(16):8913-8918 View Article PubMed/NCBI
  8. Daly NL, Koltay A, Gustafson KR, Boyd MR, Casas-Finet JR, Craik DJ. Solution structure by NMR of circulin A: a macrocyclic knotted peptide having anti-HIV activity. J Mol Biol 1999;285(1):333-345 View Article PubMed/NCBI
  9. Gustafson KR, Walton LK, Sowder RC, Johnson DG, Pannell LK, Cardellina JH, et al. New circulin macrocyclic polypeptides from Chassalia parvifolia. J Nat Prod 2000;63(2):176-178 View Article PubMed/NCBI
  10. Hernandez JF, Gagnon J, Chiche L, Nguyen TM, Andrieu JP, Heitz A, et al. Squash trypsin inhibitors from Momordica cochinchinensis exhibit an atypical macrocyclic structure. Biochemistry 2000;39(19):5722-5730 View Article PubMed/NCBI
  11. Simonsen SM, Sando L, Rosengren KJ, Wang CK, Colgrave ML, Daly NL, et al. Alanine scanning mutagenesis of the prototypic cyclotide reveals a cluster of residues essential for bioactivity. J Biol Chem 2008;283(15):9805-9813 View Article PubMed/NCBI
  12. Huang YH, Colgrave ML, Clark RJ, Kotze AC, Craik DJ. Lysine-scanning mutagenesis reveals an amendable face of the cyclotide kalata B1 for the optimization of nematocidal activity. J Biol Chem 2010;285(14):10797-10805 View Article PubMed/NCBI
  13. Wong CT, Taichi M, Nishio H, Nishiuchi Y, Tam JP. Optimal oxidative folding of the novel antimicrobial cyclotide from Hedyotis biflora requires high alcohol concentrations. Biochemistry 2011;50(33):7275-7283 View Article PubMed/NCBI
  14. Ji Y, Majumder S, Millard M, Borra R, Bi T, Elnagar AY, et al. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide. J Am Chem Soc 2013;135(31):11623-11633 View Article PubMed/NCBI
  15. Gran L. Oxytocic principles of Oldenlandia affinis. Lloydia 1973;36(2):174-178 PubMed/NCBI
  16. Gran L. On the effect of a polypeptide isolated from “Kalata-Kalata” (Oldenlandia affinis DC) on the oestrogen dominated uterus. Acta Pharmacol Toxicol (Copenh) 1973;33(5):400-408 View Article PubMed/NCBI
  17. Witherup KM, Bogusky MJ, Anderson PS, Ramjit H, Ransom RW, Wood T, et al. Cyclopsychotride A, a biologically active, 31-residue cyclic peptide isolated from Psychotria longipes. J Nat Prod 1994;57(12):1619-1625 View Article PubMed/NCBI
  18. Gruber CW, Elliott AG, Ireland DC, Delprete PG, Dessein S, Göransson U, et al. Distribution and evolution of circular miniproteins in flowering plants. Plant Cell 2008;20(9):2471-2483 View Article PubMed/NCBI
  19. Trabi M, Craik DJ. Tissue-specific expression of head-to-tail cyclized miniproteins in Violaceae and structure determination of the root cyclotide Viola hederacea root cyclotide1. Plant Cell 2004;16(8):2204-2216 View Article PubMed/NCBI
  20. Velásquez JE, van der Donk WA. Genome mining for ribosomally synthesized natural products. Curr Opin Chem Biol 2011;15(1):11-21 View Article PubMed/NCBI
  21. Hellinger R, Koehbach J, Soltis DE, Carpenter EJ, Wong GK, Gruber CW. Peptidomics of circular cysteine-rich plant peptides: analysis of the diversity of cyclotides from Viola tricolor by transcriptome and proteome mining. J Proteome Res 2015;14(11):4851-4862 View Article PubMed/NCBI
  22. Mulvenna JP, Wang C, Craik DJ. CyBase: a database of cyclic protein sequence and structure. Nucleic Acids Res 2006;34(Database issue):D192-D194 View Article PubMed/NCBI
  23. Herrmann A, Burman R, Mylne JS, Karlsson G, Gullbo J, Craik DJ, et al. The alpine violet, Viola biflora, is a rich source of cyclotides with potent cytotoxicity. Phytochemistry 2008;69(4):939-952 View Article PubMed/NCBI
  24. Saska I, Gillon AD, Hatsugai N, Dietzgen RG, Hara-Nishimura I, Anderson MA, et al. An asparaginyl endopeptidase mediates in vivo protein backbone cyclization. J Biol Chem 2007;282(40):29721-29728 View Article PubMed/NCBI
  25. Gillon AD, Saska I, Jennings CV, Guarino RF, Craik DJ, Anderson MA. Biosynthesis of circular proteins in plants. Plant J 2008;53(3):505-515 View Article PubMed/NCBI
  26. Conlan BF, Colgrave ML, Gillon AD, Guarino R, Craik DJ, Anderson MA. Insights into processing and cyclization events associated with biosynthesis of the cyclic Peptide kalata B1. J Biol Chem 2012;287(33):28037-28046 View Article PubMed/NCBI
  27. Craik DJ, Daly NL, Bond T, Waine C. Plant cyclotides: A unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif. J Mol Biol 1999;294(5):1327-1336 View Article PubMed/NCBI
  28. Chiche L, Heitz A, Gelly JC, Gracy J, Chau PT, Ha PT, et al. Squash inhibitors: from structural motifs to macrocyclic knottins. Curr Protein Pept Sci 2004;5(5):341-349 View Article PubMed/NCBI
  29. Chan LY, Gunasekera S, Henriques ST, Worth NF, Le SJ, Clark RJ, et al. Engineering pro-angiogenic peptides using stable, disulfide-rich cyclic scaffolds. Blood 2011;118(25):6709-6717 View Article PubMed/NCBI
  30. Wang CC, Chen JJ, Yang PC. Multifunctional transcription factor YY1: a therapeutic target in human cancer?. Expert Opin Ther Targets 2006;10(2):253-266 View Article PubMed/NCBI
  31. Camarero JA. Legume cyclotides shed light on the genetic origin of knotted circular proteins. Proc Natl Acad Sci U S A 2011;108(25):10025-10026 View Article PubMed/NCBI
  32. Poth AG, Colgrave ML, Lyons RE, Daly NL, Craik DJ. Discovery of an unusual biosynthetic origin for circular proteins in legumes. Proc Natl Acad Sci U S A 2011;108(25):10127-10132 View Article PubMed/NCBI
  33. Aboye T, Meeks CJ, Majumder S, Shekhtman A, Rodgers K, Camarero JA. Design of a MCoTI-based cyclotide with angiotensin (1-7)-like activity. Molecules 2016;21(2):152 View Article PubMed/NCBI
  34. Gilding EK, Jackson MA, Poth AG, Henriques ST, Prentis PJ, Mahatmanto T, et al. Gene coevolution and regulation lock cyclic plant defence peptides to their targets. New Phytol 2016;210(2):717-730 View Article PubMed/NCBI
  35. Gould A, Camarero JA. Cyclotides: overview and biotechnological applications. Chembiochem 2017;18(14):1350-1363 View Article PubMed/NCBI
  36. Craik DJ, Du J. Cyclotides as drug design scaffolds. Curr Opin Chem Biol 2017;38:8-16 View Article PubMed/NCBI
  37. Rosengren KJ, Daly NL, Plan MR, Waine C, Craik DJ. Twists, knots, and rings in proteins. Structural definition of the cyclotide framework. J Biol Chem 2003;278(10):8606-8616 View Article PubMed/NCBI
  38. Daly NL, Rosengren KJ, Craik DJ. Discovery, structure and biological activities of cyclotides. Adv Drug Deliv Rev 2009;61(11):918-930 View Article PubMed/NCBI
  39. Colgrave ML, Kotze AC, Ireland DC, Wang CK, Craik DJ. The anthelmintic activity of the cyclotides: natural variants with enhanced activity. Chembiochem 2008;9(12):1939-1945 View Article PubMed/NCBI
  40. Fensterseifer IC, Silva ON, Malik U, Ravipati AS, Novaes NR, Miranda PR, et al. Effects of cyclotides against cutaneous infections caused by Staphylococcus aureus. Peptides 2015;63:38-42 View Article PubMed/NCBI
  41. Ireland DC, Colgrave ML, Craik DJ. A novel suite of cyclotides from Viola odorata: sequence variation and the implications for structure, function and stability. Biochem J 2006;400(1):1-12 View Article PubMed/NCBI
  42. Lindholm P, Göransson U, Johansson S, Claeson P, Gullbo J, Larsson R, et al. Cyclotides: a novel type of cytotoxic agents. Mol Cancer Ther 2002;1(6):365-369 PubMed/NCBI
  43. Svangård E, Göransson U, Hocaoglu Z, Gullbo J, Larsson R, Claeson P, et al. Cytotoxic cyclotides from Viola tricolor. J Nat Prod 2004;67(2):144-147 View Article PubMed/NCBI
  44. Esmaeili MA, Abagheri-Mahabadi N, Hashempour H, Farhadpour M, Gruber CW, Ghassempour A. Viola plant cyclotide vigno 5 induces mitochondria-mediated apoptosis via cytochrome C release and caspases activation in cervical cancer cells. Fitoterapia 2016;109:162-168 View Article PubMed/NCBI
  45. Aboye TL, Ha H, Majumder S, Christ F, Debyser Z, Shekhtman A, et al. Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. J Med Chem 2012;55(23):10729-10734 View Article PubMed/NCBI
  46. Guzmán-Rodríguez JJ, Ochoa-Zarzosa A, López-Gómez R, López-Meza JE. Plant antimicrobial peptides as potential anticancer agents. Biomed Res Int 2015;2015:735087 View Article PubMed/NCBI
  47. Grover T, Mishra R, Gulati P, Mohanty A, Bushra. An insight into biological activities of native cyclotides for potential applications in agriculture and pharmaceutics. Peptides 2021;135:170430 View Article PubMed/NCBI
  48. Nguyen GK, Zhang S, Nguyen NT, Nguyen PQ, Chiu MS, Hardjojo A, et al. Discovery and characterization of novel cyclotides originated from chimeric precursors consisting of albumin-1 chain a and cyclotide domains in the Fabaceae family. J Biol Chem 2011;286(27):24275-24287 View Article PubMed/NCBI
  49. Ding X, Bai D, Qian J. Novel cyclotides from Hedyotis biflora inhibit proliferation and migration of pancreatic cancer cell in vitro and in vivo. Med Chem Res 2014;23:1406-1413 View Article
  50. Pinto MEF, Najas JZG, Magalhães LG, Bobey AF, Mendonça JN, Lopes NP, et al. Inhibition of breast cancer cell migration by cyclotides isolated from Pombalia calceolaria. J Nat Prod 2018;81(5):1203-1208 View Article PubMed/NCBI
  51. Gerlach SL, Rathinakumar R, Chakravarty G, Göransson U, Wimley WC, Darwin SP, et al. Anticancer and chemosensitizing abilities of cycloviolacin 02 from Viola odorata and psyle cyclotides from Psychotria leptothyrsa. Biopolymers 2010;94(5):617-625 View Article PubMed/NCBI
  52. Nguyen GKT, Lim WH, Nguyen PQT, Tam JP. Novel cyclotides and uncyclotides with highly shortened precursors from Chassalia chartacea and effects of methionine oxidation on bioactivities. J Biol Chem 2012;287(21):17598-17607 View Article PubMed/NCBI
  53. Sen Z, Zhan XK, Jing J, Yi Z, Wanqi Z. Chemosensitizing activities of cyclotides from Clitoria ternatea in paclitaxel-resistant lung cancer cells. Oncol Lett 2013;5(2):641-644 View Article PubMed/NCBI
  54. Strömstedt AA, Park S, Burman R, Göransson U. Bactericidal activity of cyclotides where phosphatidylethanolamine-lipid selectivity determines antimicrobial spectra. Biochim Biophys Acta Biomembr 2017;1859(10):1986-2000 View Article PubMed/NCBI
  55. Burman R, Herrmann A, Tran R, Kivelä JE, Lomize A, Gullbo J, et al. Cytotoxic potency of small macrocyclic knot proteins: structure-activity and mechanistic studies of native and chemically modified cyclotides. Org Biomol Chem 2011;9(11):4306-4314 View Article PubMed/NCBI
  56. Parsley NC, Kirkpatrick CL, Crittenden CM, Rad JG, Hoskin DW, Brodbelt JS, et al. PepSAVI-MS reveals anticancer and antifungal cycloviolacins in Viola odorata. Phytochemistry 2018;152:61-70 View Article PubMed/NCBI
  57. Ravipati AS, Henriques ST, Poth AG, Kaas Q, Wang CK, Colgrave ML, et al. Lysine-rich cyclotides: a new subclass of circular knotted proteins from Violaceae. ACS Chem Biol 2015;10(11):2491-2500 View Article PubMed/NCBI
  58. Yeshak MY, Burman R, Asres K, Göransson U. Cyclotides from an extreme habitat: characterization of cyclic peptides from Viola abyssinica of the Ethiopian highlands. J Nat Prod 2011;74(4):727-731 View Article PubMed/NCBI
  59. He W, Chan LY, Zeng G, Daly NL, Craik DJ, Tan N. Isolation and characterization of cytotoxic cyclotides from Viola philippica. Peptides 2011;32(8):1719-1723 View Article PubMed/NCBI
  60. Gerlach SL, Dunlop RA, Metcalf JS, Banack SA, Cox PA. Cyclotides chemosensitize glioblastoma cells to temozolomide. J Nat Prod 2022;85(1):34-46 View Article PubMed/NCBI
  61. Du Q, Huang YH, Wang CK, Kaas Q, Craik DJ. Mutagenesis of bracelet cyclotide hyen D reveals functionally and structurally critical residues for membrane binding and cytotoxicity. J Biol Chem 2022;298(4):101822 View Article PubMed/NCBI
  62. Dong J, Zhang X, Qu C, Rong X, Liu J, Qu Y. Retracted Article: Structural characterization of Momordica charantia L. (Cucurbitaceae) oligopeptides and the detection of their capability in non-small cell lung cancer A549 cells: induction of apoptosis. RSC Adv 2019;9(15):8300-8309 View Article PubMed/NCBI
  63. Deesrisak K, Yingchutrakul Y, Krobthong S, Roytrakul S, Chatupheeraphat C, Subkorn P, et al. Bioactive peptide isolated from sesame seeds inhibits cell proliferation and induces apoptosis and autophagy in leukemic cells. EXCLI J 2021;20:709-721 View Article PubMed/NCBI
  64. Hu E, Wang D, Chen J, Tao X. Novel cyclotides from Hedyotis diffusa induce apoptosis and inhibit proliferation and migration of prostate cancer cells. Int J Clin Exp Med 2015;8(3):4059-4065 PubMed/NCBI
  65. Okinyo-Owiti DP, Dong Q, Ling B, Jadhav PD, Bauer R, Maley JM, et al. Evaluating the cytotoxicity of flaxseed orbitides for potential cancer treatment. Toxicol Rep 2015;2:1014-1018 View Article PubMed/NCBI
  66. Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ. Cyclotides as natural anti-HIV agents. Biopolymers 2008;90(1):51-60 View Article PubMed/NCBI
  67. Gustafson KR, Sowder RC, Henderson LE, Parsons IC, Kashman Y, Cardellina JH, et al. Circulins A and B. Novel human immunodeficiency virus (HIV)-inhibitory macrocyclic peptides from the tropical tree Chassalia parvifolia. J Am Chem Soc 1994;116(20):9337-9338 View Article
  68. Hallock YF, Sowder RC, Pannell LK, Hughes CB, Johnson DG, Gulakowski R, et al. Cycloviolins A-D, anti-HIV macrocyclic peptides from Leonia cymosa. J Org Chem 2000;65(1):124-128 View Article PubMed/NCBI
  69. Wang CK, Colgrave ML, Gustafson KR, Ireland DC, Goransson U, Craik DJ. Anti-HIV cyclotides from the Chinese medicinal herb Viola yedoensis. J Nat Prod 2008;71(1):47-52 View Article PubMed/NCBI
  70. Chen B, Colgrave ML, Daly NL, Rosengren KJ, Gustafson KR, Craik DJ. Isolation and characterization of novel cyclotides from Viola hederaceae: solution structure and anti-HIV activity of vhl-1, a leaf-specific expressed cyclotide. J Biol Chem 2005;280(23):22395-22405 View Article PubMed/NCBI
  71. Bokesch HR, Pannell LK, Cochran PK, Sowder RC, McKee TC, Boyd MR. A novel anti-HIV macrocyclic peptide from Palicourea condensata. J Nat Prod 2001;64(2):249-250 View Article PubMed/NCBI
  72. Gründemann C, Thell K, Lengen K, Garcia-Käufer M, Huang YH, Huber R, et al. Cyclotides suppress human T-Lymphocyte proliferation by an interleukin 2-dependent mechanism. PLoS One 2013;8(6):e68016 View Article PubMed/NCBI
  73. Hellinger R, Thell K, Vasileva M, Muhammad T, Gunasekera S, Kümmel D, et al. Chemical proteomics for target discovery of head-to-tail cyclized mini-proteins. Front Chem 2017;5:73 View Article PubMed/NCBI
  74. Gründemann C, Stenberg KG, Gruber CW. T20K: An immunomodulatory cyclotide on its way to the clinic. Int J Pept Res Ther 2019;25:9-13 View Article
  75. Pinto MEF, Chan LY, Koehbach J, Devi S, Gründemann C, Gruber CW, et al. Cyclotides from Brazilian Palicourea sessilis and their effects on human lymphocytes. J Nat Prod 2021;84(1):81-90 View Article PubMed/NCBI
  76. Garcia AE, Camarero JA. Biological activities of natural and engineered cyclotides, a novel molecular scaffold for peptide-based therapeutics. Curr Mol Pharmacol 2010;3(3):153-163 View Article PubMed/NCBI
  77. Gunasekera S, Foley FM, Clark RJ, Sando L, Fabri LJ, Craik DJ, et al. Engineering stabilized vascular endothelial growth factor-A antagonists: synthesis, structural characterization, and bioactivity of grafted analogues of cyclotides. J Med Chem 2008;51(24):7697-7704 View Article PubMed/NCBI
  78. Thongyoo P, Bonomelli C, Leatherbarrow RJ, Tate EW. Potent inhibitors of beta-tryptase and human leukocyte elastase based on the MCoTI-II scaffold. J Med Chem 2009;52(20):6197-6200 View Article PubMed/NCBI
  79. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004;14(3):171-179 View Article PubMed/NCBI
  80. Eliasen R, Daly NL, Wulff BS, Andresen TL, Conde-Frieboes KW, Craik DJ. Design, synthesis, structural and functional characterization of novel melanocortin agonists based on the cyclotide kalata B1. J Biol Chem 2012;287(48):40493-40501 View Article PubMed/NCBI
  81. Bernhard WR, Thoma S, Botella J, Somerville CR. Isolation of a cDNA Clone for spinach lipid transfer protein and evidence that the protein is synthesized by the secretory pathway. Plant Physiol 1991;95(1):164-170 View Article PubMed/NCBI
  82. Choi YE, Lim S, Kim HJ, Han JY, Lee MH, Yang Y, et al. Tobacco NtLTP1, a glandular-specific lipid transfer protein, is required for lipid secretion from glandular trichomes. Plant J 2012;70(3):480-491 View Article PubMed/NCBI
  83. Chae K, Kieslich CA, Morikis D, Kim SC, Lord EM. A gain-of-function mutation of Arabidopsis lipid transfer protein 5 disturbs pollen tube tip growth and fertilization. Plant Cell 2009;21(12):3902-3914 View Article PubMed/NCBI
Copyright © 2022 Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • Journal of Exploratory Research in Pharmacology
  • pISSN 2993-5121
  • eISSN 2572-5505

Article Options

Metrics

Cite this Article

  • © 2024 Xia & He Publishing Inc.
  • Total visits : 2757986
  • Visits today : 2657
Back to Top

Structures, Functions and Therapeutic Potential of Cyclotides

Sarfuddin Azmi, Mohammad Mustafa, Shoaib Shoaib, Mohd Kamil Hussain
  • Reset Zoom
  • Download TIFF